Introduction to Downstream Processing for Plant-Based Biologics

Plant-based biologics represent a transformative shift in pharmaceutical manufacturing, leveraging genetically modified plants such as tobacco, duckweed, or moss to produce therapeutic proteins, antibodies, and vaccines. These systems offer significant advantages over traditional microbial or mammalian cell cultures: lower capital investment, reduced risk of human pathogen contamination, and the ability to produce complex proteins at a fraction of the cost. However, the success of plant-made biologics depends heavily on efficient downstream processing — the series of steps that isolate, purify, and formulate the target biologic from raw plant biomass.

Downstream processing is often the costliest and most technically demanding phase of production, accounting for up to 80% of total manufacturing expenses. In plant-based systems, the challenges are amplified by the presence of pigments, fibers, oils, phenolics, and a wide variety of host cell proteins. The concentration of the target protein in plant tissue is typically low, requiring large volumes of raw material to be processed. To meet commercial and regulatory demands, manufacturers must adopt advanced technologies that maximize purity, yield, and scalability while minimizing costs and environmental impact.

This article explores the emerging technologies that are reshaping downstream processing for plant-based biologics, providing detailed insights into how these innovations are overcoming historical bottlenecks and enabling a new generation of therapeutics.

Key Challenges in Downstream Processing of Plant-Based Biologics

Before examining the technologies, it is important to understand the specific hurdles that plant-based systems present:

  • Complex feed streams: Plant extracts contain cellulose, lignin, starches, and secondary metabolites that can clog filters, foul chromatography columns, and co-purify with the target protein.
  • Low protein concentration: Unlike high-expression microbial systems, plant tissues often accumulate protein at lower levels, meaning larger volumes of extract must be processed to obtain a gram of product.
  • Proteolytic degradation: Plant cells contain endogenous proteases that can degrade the recombinant product if not quickly inactivated or removed during initial recovery steps.
  • Regulatory compliance: The FDA and EMA require rigorous impurity removal and process validation, which can be more difficult with heterogeneous plant material.
  • Scalability: Processes developed at lab scale often fail to translate to commercial volumes due to differences in mixing, mass transfer, and particulate behavior.

Addressing these challenges is the driving force behind the emerging technologies described below.

Emerging Technologies in Downstream Processing

Affinity Chromatography with Novel Ligands

Affinity chromatography remains the gold standard for high-purity capture of biologics, particularly for antibodies and Fc-fusion proteins. In plant-based processing, the major limitation has been the cost and stability of traditional Protein A resins. Emerging innovations focus on engineered ligands, such as small peptide mimetics, aptamers, or synthetic protein domains that offer comparable selectivity at a fraction of the cost. For example, MabSelect PrismA and similar resins combine high dynamic binding capacity with alkali stability, enabling cleaning-in-place protocols that extend resin lifetime — critical for large-scale plant processing.

Additionally, the use of mixed-mode ligands (e.g., Capto MMC or Capto Adhere from Cytiva) allows both affinity and ion-exchange interactions, improving clearance of plant-specific impurities such as chlorophyll and phenolics. Recent literature demonstrates that engineered ligands can selectively bind plant-produced antibodies with yields exceeding 90% and purity levels suitable for clinical use.

Advanced Membrane Filtration: TFF and Beyond

Membrane filtration is a workhorse in downstream processing, used for clarification, concentration, and buffer exchange. Tangential flow filtration (TFF) is particularly well-suited for plant extracts because it handles high solids loads and reduces membrane fouling compared to dead-end filtration. Recent advances include:

  • High-performance polymeric membranes with tuned pore sizes and hydrophilic coatings that resist fouling by plant polysaccharides.
  • Single-use TFF assemblies that eliminate cleaning validation and reduce cross-contamination risk — ideal for multiproduct plant facilities.
  • Ultrasonic filtration assistance that uses acoustic waves to keep particles suspended near the membrane surface, increasing flux by 30-50%.

In addition to TFF, ultrafiltration (UF) and nanofiltration are being optimized for virus removal and final polishing of plant-derived proteins. The adoption of higher permeability membranes, such as those based on polyethersulfone or regenerated cellulose, allows for faster processing while maintaining high retention of the target biologic.

Continuous Processing and Integrated Systems

The transition from batch to continuous processing is perhaps the most transformative trend in biologics manufacturing. For plant-based systems, continuous downstream processing can significantly improve productivity and reduce capital footprint. Key developments include:

  • Continuous countercurrent chromatography (e.g., simulated moving bed or periodic counter-current chromatography) that maximizes resin utilization and reduces buffer consumption.
  • Multicolumn integrated systems that allow capture, wash, elution, and regeneration to occur simultaneously in different columns, increasing throughput by 2-3x over batch operations.
  • Inline conditioning of feed streams using real-time process analytical technology (PAT) to adjust pH or conductivity before entering the column.

Companies like Sartorius and Cytiva offer modular, skid-mounted platforms that integrate clarification, capture, and polishing in a single continuous train. These systems are specifically designed to handle the high particulate loads and variable viscosity of plant extracts.

Aqueous Two-Phase Extraction (ATPS)

ATPS uses two immiscible aqueous phases — typically a polymer-rich phase (e.g., polyethylene glycol) and a salt-rich phase (e.g., phosphate or citrate) — to partition the target protein into one phase while contaminants migrate to the other. This technique is gaining traction for plant-based biologics because it can be performed directly on clarified (or even non-clarified) extracts, simplifying the initial recovery step. Benefits include:

  • Gentle conditions that preserve protein activity and minimize aggregation.
  • Ability to remove pigments, oils, and cell debris in a single step.
  • Ease of scale-up using simple mixing and settling tanks, without expensive resins or membranes.

Recent studies have demonstrated ATPS yields of >80% for plant-derived monoclonal antibodies, with purity comparable to Protein A capture. Research on PEG-salt systems optimized for Nicotiana benthamiana extracts shows that careful selection of molecular weight and tie-line length can tune selectivity dramatically.

Precipitation and Crystallization

Precipitation using non-denaturing agents (e.g., ammonium sulfate, caprylic acid) remains a simple and scalable method for initial enrichment of plant biologics. Emerging approaches use affinity precipitation where a responsive polymer (e.g., temperature-sensitive PNIPAAm or pH-sensitive chitosan) conjugated with a capture ligand is added to the extract. The target protein binds to the polymer, which is then precipitated by a mild trigger (heat or pH change) and recovered by centrifugation or filtration.

Protein crystallization, long used for small molecules, is being adapted for biologics as a final polishing step that simultaneously concentrates and purifies. Crystallization can remove trace impurities and produce a stable, high-density solid that facilitates formulation and filling. Companies like Roche have explored crystallization for antibody purification, and the same principles can be applied to plant-made biologics with proper control of supersaturation and seeding. While crystallization is still emerging, it offers the promise of eliminating two or more chromatography steps.

Single-Use Technologies for Plant Processing

The biopharmaceutical industry is increasingly adopting single-use (disposable) equipment for upstream and downstream operations. For plant-based biologics, single-use technologies provide distinct advantages:

  • Elimination of cleaning validation between batches, reducing turnaround time and water usage.
  • Flexibility to switch between different plant lines or target proteins without cross-contamination risk.
  • Lower capital investment for facilities that process seasonal or niche crops.

Disposable bags and tubing are now used for homogenization, centrifugation, and TFF steps. Newer developments include single-use packed-bed chromatography columns (e.g., aseptic-packed columns from Repligen or prepacked columns from GE Healthcare) that are pre-validated and ready to run. For plant extracts with high fiber content, single-use depth filters with diatomaceous earth or cellulose-based media effectively clarify the feed before chromatography.

Process Analytical Technology (PAT) and Artificial Intelligence

Real-time monitoring and control are essential for consistent downstream processing of plant biologics, where feedstock variability is unavoidable. PAT tools such as near-infrared spectroscopy, Raman spectroscopy, and HPLC-based at-line analyzers allow operators to measure product concentration, purity, and impurity levels during the run. This data feeds into multivariate statistical process control models that detect drift and adjust parameters (e.g., elution gradient, flow rate) in real time.

Artificial intelligence and machine learning are beginning to play a role in process optimization. For example, reinforcement learning algorithms can train controllers to maximize yield while minimizing buffer usage, by exploring different operating conditions in silico. Companies like Benchling and Insilico Medicine are developing bioprocess simulation platforms that integrate PAT data and predict optimal downstream configurations for plant-derived biologics.

Benefits of Emerging Technologies for Plant-Based Biologics

The cumulative impact of these technologies extends beyond individual step improvements. When combined, they enable:

  • Higher purity and safety: Advanced affinity ligands and multistep continuous processes remove host cell proteins, DNA, and plant-specific contaminants like alkaloids and chlorophyll breakdown products. This ensures compliance with regulatory requirements for injectable biologics.
  • Reduced processing time and cost: Continuous systems cut batch cycles from days to hours. Single-use equipment eliminates cleaning and sterilization downtime. ATPS and precipitation reduce reliance on expensive chromatography resins.
  • True scalability: Membrane-based operations are linear, making scale-up straightforward. Continuous platforms are modular — multiple identical trains can be run in parallel to increase capacity without altering process conditions.
  • Environmental sustainability: Green solvents (aqueous-only in ATPS), lower energy consumption (continuous filtration vs. high-pressure columns), and reduced water and chemical usage (single-use eliminates cleaning) align with global sustainability goals.
  • Faster regulatory approval: Well-characterized, PAT-controlled processes with in-line monitoring provide regulators with robust data packages, reducing the risk of manufacturing-related delays during clinical development.

Future Directions and Outlook

The field of plant-based biologics downstream processing is evolving rapidly, driven by converging trends in automation, materials science, and data analytics. Several key areas are poised for breakthroughs in the next five years:

  • Fully integrated end-to-end continuous processing from harvest to final drug product, with minimal intermediate hold steps. Pilot demonstrations using plant extracts have shown feasibility, and commercial-scale installations are on the horizon.
  • Advanced affinity ligands with enhanced specificity for non-antibody biologics such as enzymes, growth factors, and hormones. Phage display and computational design are generating libraries of peptides and small proteins that can be rapidly screened for plant-derived targets.
  • In-field processing using mobile, pod-scale equipment that can be deployed near the farms where plants are grown. This would drastically reduce biomass shipping costs and degradation risks.
  • Digital twins of downstream processes that combine mechanistic models (e.g., transport phenomena, chromatography breakthrough) with real-time sensor data to predict performance and optimize settings for each batch.

As the COVID-19 pandemic demonstrated, plant-based platforms can respond quickly to emerging health threats — provided that downstream processing can keep pace. Investments in the technologies described here are essential to unlocking the full potential of plants as a sustainable, scalable, and safe source of complex biologics.

Conclusion

Downstream processing remains the critical path in the commercialization of plant-based biologics. Emerging technologies — including next-generation affinity chromatography, advanced membrane filtration, continuous integrated systems, aqueous two-phase extraction, precipitation/crystallization, single-use equipment, and AI-driven PAT — are collectively addressing the longstanding bottlenecks of yield, purity, cost, and scalability. By adopting these innovations, manufacturers can transform plant-derived biologics from a niche alternative into a mainstream platform that meets global demand for affordable, safe therapeutics.

The pace of adoption will depend on continued collaboration between academic researchers, technology vendors, and biopharmaceutical companies. With the right investments in process development and regulatory science, the next decade will likely see plant-based biologics delivered to patients through manufacturing processes that are as green and efficient as the plants themselves.